Evidence map›Paper›PMID 24454917›Full record

ArticlePloS one2014

Optimizing viable leukocyte sampling from the female genital tract for clinical trials: an international multi-site study.

Lyle R McKinnon, Sean M Hughes, Stephen C De Rosa, Jeffrey A Martinson, Jill Plants, Kirsten E Brady, Pamela P Gumbi, Devin J Adams, Lucia Vojtech, Christine G Galloway and 16 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06686043 (A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers), which is not on this map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06686043 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2 Study of HPV L1 Vaccine in Combination With Imiquimod and Metformin in Cervical, Vaginal, and Vulvar Cancers

TypeinterventionalSponsorBaylor College of MedicineRan2024 to 2028Enrolled85ConditionsCervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated CarcinomaArmsHPV vaccine, Imiquimod, and metformin combination therapy
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. T-Cell Biology in the Female Reproductive Tract: Relevance to HIV Infection.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  3. Novel Approaches for Investigating Host Responses to HIV Infection in Ex Vivo Human Genital Tissues.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Innate Immune Protection Against HIV in the Female Genital Tract.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  5. Article
  6. UnveilingiScience · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Open forum infectious diseases · 2022
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Betamethasone induces potent immunosuppression and reduces HIV infection in a PBMC in vitro model.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2021
    Article
  19. OMIP-070: NKp46-Based 27-Color Phenotyping to Define Natural Killer Cells Isolated From Human Tumor Tissues.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 7 institutions in 4 countries.

Lyle R McKinnonDepartment of Medicine, University of Toronto, Toronto, Canada ; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
Sean M HughesDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America.
Jeffrey A MartinsonDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Jill PlantsDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Kirsten E BradyDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Pamela P GumbiInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Devin J AdamsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Lucia VojtechDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.
Christine G GallowayVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Michael FialkowDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.
Gretchen LentzDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America.
Dayong GaoDepartment of Mechanical Engineering, University of Washington, Seattle, Washington, United States of America.
Zhiquan ShuDepartment of Mechanical Engineering, University of Washington, Seattle, Washington, United States of America.
Billy NyangaDepartment of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
Preston IzullaDepartment of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
Joshua KimaniDepartment of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
Steve KimwakiDepartment of Medical Microbiology, University of Nairobi, Nairobi, Kenya.
Alfred BereInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Zoe MoodieVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Alan L LandayDepartment of Immunology and Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America.
Jo-Ann S PassmoreInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa ; National Health Laboratory Services, Cape Town, South Africa.
Rupert KaulDepartment of Medicine, University of Toronto, Toronto, Canada ; Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya ; Department of Medicine, University Health Network, Toronto, Canada.
Richard M NovakCollege of Medicine, University of Illinois, Chicago, Illinois, United States of America.
M Juliana McElrathVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Department of Medicine, University of Washington, Seattle, Washington, United States of America ; Department of Laboratory Medicine, University of Washington, Seattle, Washington, United States of America ; Department of Global Health, University of Washington, Seattle, Washington, United States of America.
Florian HladikDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, United States of America ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America ; Department of Medicine, University of Washington, Seattle, Washington, United States of America.
University of Washington · USUniversity of Nairobi · KERush University Medical Center · USFred Hutch Cancer Center · USUniversity of Cape Town · ZAIllinois College · USUniversity of Toronto · CA

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
LC: HIV Vaccine Trials NetworkUM1AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Margaret Juliana McElrath · 2011 to 2026
$483.6M
SDMC: HIV Vaccine Trials NetworkUM1AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Peter B. Gilbert, Yunda Huang · 2011 to 2026
$385.9M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
HVTN Laboratory ProgramU01AI068618 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MCELRATH, MARGARET JULIANA · 2006 to 2010
$82.6M
Leadership for HIV/AIDS Clinical Trials Networks; HIV Vaccine Trials NetworkU01AI068635 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SELF, STEVEN G. · 2006 to 2010
$53.8M
CIHR MOP-89983NIAID NIH HHS UM1 AI068618NIAID NIH HHS UM1AI068618NIAID NIH HHS UM1 AI068635NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1AI068636
6 · The paper itself

Abstract

backgroundFunctional analysis of mononuclear leukocytes in the female genital mucosa is essential for understanding the immunologic effects of HIV vaccines and microbicides at the site of HIV exposure. However, the best female genital tract sampling technique is unclear. METHODS AND

findingsWe enrolled women from four sites in Africa and the US to compare three genital leukocyte sampling methods: cervicovaginal lavages (CVL), endocervical cytobrushes, and ectocervical biopsies. Absolute yields of mononuclear leukocyte subpopulations were determined by flow cytometric bead-based cell counting. Of the non-invasive sampling types, two combined sequential cytobrushes yielded significantly more viable mononuclear leukocytes than a CVL (p<0.0001). In a subsequent comparison, two cytobrushes yielded as many leukocytes (∼ 10,000) as one biopsy, with macrophages/monocytes being more prominent in cytobrushes and T lymphocytes in biopsies. Sample yields were consistent between sites. In a subgroup analysis, we observed significant reproducibility between replicate same-day biopsies (r = 0.89, p = 0.0123). Visible red blood cells in cytobrushes increased leukocyte yields more than three-fold (p = 0.0078), but did not change their subpopulation profile, indicating that these leukocytes were still largely derived from the mucosa and not peripheral blood. We also confirmed that many CD4(+) T cells in the female genital tract express the α4β7 integrin, an HIV envelope-binding mucosal homing receptor.

conclusionsCVL sampling recovered the lowest number of viable mononuclear leukocytes. Two cervical cytobrushes yielded comparable total numbers of viable leukocytes to one biopsy, but cytobrushes and biopsies were biased toward macrophages and T lymphocytes, respectively. Our study also established the feasibility of obtaining consistent flow cytometric analyses of isolated genital cells from four study sites in the US and Africa. These data represent an important step towards implementing mucosal cell sampling in international clinical trials of HIV prevention.

Indexed as

AdolescentAdultBiopsyCell SeparationCell SurvivalClinical Trials as TopicFemaleHIV InfectionsHumansLeukocytes, MononuclearReproducibility of ResultsTherapeutic IrrigationVaginaYoung Adult

Identifiers

PMID24454917
PMCPMC3893217
OpenAlexW2042074909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.